A detailed history of Northern Trust Corp transactions in Arcellx, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 384,108 shares of ACLX stock, worth $29 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
384,108
Previous 350,580 9.56%
Holding current value
$29 Million
Previous $19.3 Million 65.78%
% of portfolio
0.01%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$50.91 - $86.61 $1.71 Million - $2.9 Million
33,528 Added 9.56%
384,108 $32.1 Million
Q2 2024

Aug 14, 2024

SELL
$49.74 - $66.98 $441,691 - $594,782
-8,880 Reduced 2.47%
350,580 $19.3 Million
Q1 2024

May 14, 2024

SELL
$51.85 - $73.49 $205,377 - $291,093
-3,961 Reduced 1.09%
359,460 $25 Million
Q4 2023

Feb 13, 2024

SELL
$31.75 - $57.99 $127,952 - $233,699
-4,030 Reduced 1.1%
363,421 $20.2 Million
Q3 2023

Nov 13, 2023

BUY
$31.51 - $37.4 $248,960 - $295,497
7,901 Added 2.2%
367,451 $13.2 Million
Q2 2023

Aug 11, 2023

BUY
$27.49 - $46.9 $2.57 Million - $4.38 Million
93,386 Added 35.09%
359,550 $11.4 Million
Q1 2023

May 15, 2023

SELL
$26.92 - $33.94 $291,112 - $367,027
-10,814 Reduced 3.9%
266,164 $8.2 Million
Q4 2022

Feb 13, 2023

BUY
$17.18 - $33.0 $371,465 - $713,526
21,622 Added 8.47%
276,978 $8.58 Million
Q3 2022

Nov 14, 2022

BUY
$16.67 - $22.04 $2.64 Million - $3.5 Million
158,632 Added 164.0%
255,356 $4.79 Million
Q2 2022

Aug 12, 2022

BUY
$7.21 - $24.43 $76,570 - $259,446
10,620 Added 12.33%
96,724 $1.75 Million
Q1 2022

May 13, 2022

BUY
$12.97 - $19.14 $1.12 Million - $1.65 Million
86,104 New
86,104 $1.21 Million

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.31B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.